Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | UGCG | Q16739 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18207172 | 1.00 | KMT2A (0.45) | KMT2ASMN1; SMN2TLR2PKMUGCG | |
| SCHEMBL18206043 | 0.94 | PRKCA (0.43) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18206045 | 0.94 | PRKCA (0.43) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18218942 | 0.94 | PRKCA (0.43) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18206044 | 0.94 | PRKCA (0.43) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18914900 | 0.89 | KMT2A (0.41) | KMT2ASMN1; SMN2MEN1TP53MAPT | |
| SCHEMBL18207039 | 0.88 | KLK7 (0.39) | KMT2ASMN1; SMN2PKMMEN1CYP3A4 | |
| SCHEMBL18218927 | 0.85 | ALDH1A1 (0.37) | KMT2ASMN1; SMN2MEN1CYP3A4CYP2D6 | |
| SCHEMBL18207041 | 0.84 | KLK7 (0.37) | KMT2APKMMEN1CYP3A4CYP2D6 | |
| SCHEMBL18915737 | 0.84 | KMT2A (0.39) | KMT2ASMN1; SMN2PKMMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | KMT2A 3110/4885SMN1; SMN2 252/4885TLR2 3549/4885 |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | KMT2A 3110/4885SMN1; SMN2 252/4885TLR2 3549/4885 |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | KMT2A 3110/4885SMN1; SMN2 252/4885TLR2 3549/4885 |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 3110/4885SMN1; SMN2 252/4885TLR2 3549/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 3110/4885SMN1; SMN2 252/4885TLR2 3549/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 3110/4885SMN1; SMN2 252/4885TLR2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.